2025+JPM+预览+报告_29页_3mb

The 43rd annual J.P. Morgan Healthcare Conference (JPM) in January 2025 will focus on AI-driven advancements in biotech and new collaborations in drug development. Despite progress in AI, challenges like financial scalability, lack of specialized talent, and regulatory complexities persist. AstraZeneca, Eli Lilly, Merck, AbbVie, and other major companies will discuss pipeline updates, regulatory events, and the impact of AI on therapies. Smaller firms are expected to highlight novel pipeline drugs and partnerships. ICON Biotech's biotech division supports clinical development through flexible partnership models. Companies like Moderna, Roche, and Teva will address mRNA vaccines, CAR-T therapies, and biosimilars growth, respectively. The event will drive industry collaboration and innovation in healthcare.